Ontology highlight
ABSTRACT: Background
To date, there has been little agreement on what drug is the "best" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19.Methods
We searched databases for randomized controlled trials (RCTs) published up to February 28, 2022, with no language restrictions, of medications recommended for patients (aged 16 years or older) with severe COVID-19 infection. We extracted data on trials and patient characteristics, and the following primary outcomes: all-cause mortality (ACM), and treatment-emergent adverse events (TEAEs).Results
We identified 4021 abstracts and of these included 48 RCTs comprising 9147 participants through database searches and other sourc
SUBMITTER: Cheng Q
PROVIDER: S-EPMC9575403 | biostudies-literature | 2022 Oct
REPOSITORIES: biostudies-literature